DOCSLIB.ORG

Volunteer Disclosure Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Volunteer Disclosure Report Volunteer Disclosure Report All relationships are considered compensated. Relationships are self-held unless otherwise noted. Name Employment Leadership Stock and Other Honoraria Consulting or Speakers' Research Funding Patents, Royalties, Other Expert Travel, Other Ownership Advisory Role Bureau Intellectual Property Testimony Accommodations, Interests Expenses Monica M. Bertagnolli Bruce E. Johnson KEW Chugai Pharma Amgen Genentech/Roche (Inst) #Dana-Farber Cancer AstraZeneca Genentech/Roche (Inst) Institute Boehringer GlaxoSmithKline (Inst) Ingelheim Novartis (Inst) Chugai Pharma Toshiba (Inst) KEW Lilly Merck Novartis Clifford A. Hudis Sumanta K. Pal Astellas Astellas Pharma, Medivation Pharma, Aveo, Bristol-Myers Medivation, Squibb, Eisai, Novartis Exelixis, Genentech, Ipsen, Myriad Pharmaceuticals, Novartis, Pfizer Merry Jennifer Markham Astex Astex Pharmaceuticals (Inst), Pharmaceuticals Aduro Biotech (Inst) John Heymach Bio-Tree, Cardinal Abbvie, ARIAD, AstraZeneca (Inst) Spine AstraZeneca, Boehringer Ingelheim, Bristol- Myers Squibb, Calithera Biosciences, Genentech, Medivation, Novartis, Oncomed, Synta Brian Alexander Abbvie, Precision Heath Economics, Schlesinger Associates, Bristol- Myers Squibb Nancy N. Baxter SERVIER Harold J. Burstein Warren A. Chow Novartis Novartis (Inst) William Dale Don Dizon InfiniteMD, UpToDate, Tesaro Merck Sharp & Dohme (Inst) Teva NeuHope Robert Dreicer Astellas Pharma, Genentech (Inst), Asana AstraZeneca, Bristol- Biosciences (Inst) Myers Squibb, Genentech/Roche, EMD Serono, Incyte, Pfizer Andrew S. Epstein UpToDate Patricia Ganz Intrinsic Xenon Pharma (I), Biogen (I) Keryx (I), Silarus Keryx (I) Related to iron Intrinsic LifeSciences LifeSciences (I) Intrinsic Therapeutics (I), metabolism and anemia (I); Keryx (I) LifeSciences (I), InformedDNA, Vifor of chronic disease (I); Up- Silarus Pharma (I), Lilly, to-Date royalties for Therapeutics (I), Gilead Sciences (I), section editor on Teva, Novartis, La Jolla Pharma (I) survivorship Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott Laboratories Timothy D. Gilligan WellPoint David L. Graham Medscape Biopep Solution Joshua A. Jones Smitha Krishnamurthi Nektar, Taiho Pharmaceutical, Regeneron, CytomX Therapeutics, Celgene Gary Lyman Generex Halozyme, G1 Amgen (Inst) Biotechnology Therapeutics, Coherus Biosciences Catherine S. Magid Gilead Sciences Bayer, Bristol-Myers Bristol-Myers Squibb (Inst), Diefenbach Squibb, Genentech (Inst), Incyte (Inst), Genentech/Roche, LAM Therapeutics (Inst), Merck, Seattle Merck (Inst), Millennium (Inst), Genetics Seattle Genetics (Inst) Gregory Masters Erica Mayer Myriad Genetics (Inst), Pfizer (Inst) Steven O'Day Bristol-Myers Bristol-Myers Bristol- Merck (Inst), Amgen (Inst), Squibb, Merck, Squibb, Merck, Myers Incyte (Inst) Novartis, Novartis, Amgen Squibb Amgen, Incyte Olatoyosi Odenike CTI/Baxalta, Abbvie, Celgene (Inst), Incyte (Inst), Pfizer, Jazz Astex Pharmaceuticals (Inst), Pharmaceuticals, NS Pharma (Inst), Abbvie (Inst), Gilead Sciences (Inst), Janssen Oncology (Inst), MEI Pharma (Inst), Millennium (Inst), Oncothyrapy (Inst), Agios (Inst), Jyoti Patel ARIAD, Abbvie, AstraZeneca Carlos Rodriguez-Galindo Novimmune Charles Ryan Janssen Bayer, Millennium, BIND Biosciences, Karyopharm Oncology, Ferring Therapeutics, Novartis Astellas Pharma, Bayer Michael S. Sabel Breast Cancer Ally and Melanoma Ally mobile technologies. Lidia Schapira Lynn Mara Schuchter Incyte GlaxoSmithKline (Inst), Merck (Inst), Bristol-Myers Squibb (Inst) Mario Sznol Adaptive Adaptimmune, AcademicC Biotechnologies, Agonox, Alexion ME, Clinical Amphivena, Pharmaceuticals, Care Intensity AstraZeneca/MedI Options, Therapeutics mmune, DAVAOncol Baxalta/Shire, ogy, Biodesix, Bristol- Haymarket Myers Squibb, Media, Genentech/Roche, Imedex, Ignyta, Immune Physician Design, Inovio Education Pharmaceuticals, Resource, Janssen Oncology, Prime Kyowa Hakko Kirin, Oncology, Lilly, Lion Research Biotechnologies, to Practice, Lycera, Merck Sharp TRM & Dohme, Oncology, Modulate, Vindico Molecular Partners, Nektar, Newlink Genetics, Novartis, Omniox, Pfizer, Pierre Fabre, Seattle Genetics, Symphony Evolution, Theravance, Vaccinex Shannon N. Westin AstraZeneca, AstraZeneca, Bayer, Biomarin, BioAscent, Casdin Celgene (I), Critical Outcome Capital, Clovis Technologies, Oncology, GlaxoSmithKline, Karyopharm Genentech, Gerson Therapeutics (I), Kite Pharma Lehrman Group, (I), Merck, Novartis, Tesaro Medivation, Medscape, Ovation Sciences, Roche, Vaniam Group, Vermillion, Watermark Research Partners.
Load more

Recommended publications
  • Moderna Appoints Oncology Leader Dr. Stephen Kelsey As President of Onkaido
    Moderna Appoints Oncology Leader Dr. Stephen Kelsey as President of Onkaido Former Genentech executive to lead Moderna’s first venture company, focused exclusively in novel biology for oncology drug development CAMBRIDGE, Mass., July 1, 2014— Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) TherapeuticsTM, a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna’s oncology drug development company, effective July 21. Launched in January of this year, Onkaido is Moderna’s first venture company, focused exclusively on developing and commercializing mRNA-based oncology treatments. “As we continue to grow Moderna and perfect our mRNA Therapeutics platform, we are also focused on building a transformational oncology company that will benefit patients and society. This requires hiring the best oncology talent to lead Onkaido,” said Stéphane Bancel, president and founding chief executive officer, Moderna. “Steve brings a wealth of experience in oncology drug development to his new role. His knowledge and leadership, combined with the team of Onkaido scientists and Moderna’s innovative mRNA technology, will help speed a new class of cancer drugs to patients around the world.” Dr. Kelsey has extensive pharmaceutical industry experience in oncology. After 16 years as an academic clinician, he started his industry career at Sugen, and later was vice president of hematology/oncology at Genentech. While at Genentech, Dr. Kelsey played a significant role in the development of key products Perjeta®, Kadcyla® and Erivedge®, as well as other molecules in the company’s oncology portfolio. He left Genentech in 2009 to run Geron’s oncology division, where he served for four years as executive vice president, research and development, and chief medical officer helping to develop therapeutics and vaccines to fight cancer.
    [Show full text]
  • Amgen and Incyte – the Biotechnology Acquisition
    Amgen and Incyte – the biotechnology acquisition Ana Carolina Coelho Student number: 152416013 Dissertation written under the supervision of António Luís Borges de Assunção Dissertation submitted in partial fulfilment of requirements for the MSc in Finance, at the Universidade Católica Portuguesa, May 2018 Abstract The main goal of this dissertation is to study the hypothesis of an acquisition in the biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based biotechnology company currently facing a decrease in sales, mainly due to an increase in the market share of generic drugs and the rise of biosimilar products. To offset the poor performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in the market with only two released drugs, its revenues are expected to increase significantly in the near future. The combination of these companies would allow knowledge transfer about research and development process of new drugs, a stronger position in Europe, and a higher investment power to apply in R&D. The combined company would be able to decrease the number of employees due to duplication of jobs and decrease the cost of sales, as the power over suppliers increases. The potential synergies are valued at $28,522.8 million, of which $16,739.2 million are more likely to be realized. The combined firm, after the introduction of synergies, is expected to generate the same or even higher returns than the sum of the stand- alone businesses and higher growth rates, fulfilling Amgen’s need of growth.
    [Show full text]
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • J. SCOTT MCBRIDE PARTNER ━ 54 West Hubbard Street, Chicago, IL 60654 | 312.494.4436 | [email protected]
    J. SCOTT MCBRIDE PARTNER ━ 54 West Hubbard Street, Chicago, IL 60654 | 312.494.4436 | [email protected] EDUCATION & HONORS The University of Chicago Law School, 2002, J.D., with High Honors Order of the Coif 1st Place, Hinton Moot Court The University of Chicago Law Review Northwestern University, 1994, M.S. Ed., Earned Illinois Secondary Teaching Certificate for Chemistry, Physics and German Dartmouth College, 1992, A.B., summa cum laude, High Honors in Chemistry Phi Beta Kappa Rufus Choate Scholar German Academic Exchange Service Scholarship Chandler T. White Chemistry Research Prize CLERKSHIPS Honorable Richard D. Cudahy, United States Court of Appeals for the Seventh Circuit, 2002-2003 ADMISSIONS Illinois INTELLECTUAL PROPERTY LITIGATION ViiV Healthcare v. Gilead Sciences (D. Del.) Lead trial counsel for Gilead in patent infringement case related to Gilead's Biktarvy® HIV treatment. Case pending. www.bartlit-beck.com CHICAGO 312.494.4400 DENVER 303.592.3100 J. SCOTT MCBRIDE Adverio Pharma GmbH v. Alembic Pharmaceuticals, Ltd. et al. (D. Del.) Lead trial counsel for Adverio and Bayer in Hatch-Waxman litigation relating to Bayer's Adempas® (riociguat) treatment for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. Gilead Sciences v. Mylan Pharmaceuticals (D. Del.) Lead trial counsel for Gilead in Hatch-Waxman litigation relating to Gilead's Tybost® (cobicistat) product. Case settled favorably. UroPep v. Eli Lilly (E.D. Tex.) Lead trial counsel (with my partners John Hughes) for UroPep in patent infringement action related to Lilly's Cialis product. Trial verdict for UroPep with damages of $20 million; affirmed on appeal. Regents of the Univ.
    [Show full text]
  • Cereblon and Its Downstream Substrates As Molecular Targets of Immunomodulatory Drugs
    Int J Hematol (2016) 104:293–299 DOI 10.1007/s12185-016-2073-4 PROGRESS IN HEMATOLOGY Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs Takumi Ito1,2 · Hiroshi Handa1 Received: 15 June 2016 / Revised: 19 July 2016 / Accepted: 19 July 2016 / Published online: 26 July 2016 © The Japanese Society of Hematology 2016 Abstract Thalidomide was first developed as a sedative History of immunomodulatory drugs (IMiDs) around 60 years ago, but exhibited teratogenicity, leading to serious defects such as limb deformities. Nevertheless, Immunomodulatory drugs (IMiDs) are a new class of anti- thalidomide is now recognized as a therapeutic drug for the cancer drugs for which the parent molecule is thalidomide. treatment of Hansen’s disease and myeloma. Immunomod- Thalidomide (Fig. 1) was developed as a sedative in 1950s ulatory drugs (IMiDs), a new class of anti-cancer drug by the German pharmaceutical company Grunenthal. derived from thalidomide, have also been developed and Experiments using rodents initially suggested it to be safe exert potent anti-cancer effects. Although the molecular for use in humans, and the drug was sold over 40 countries, mechanism of thalidomide and IMiDs remained unclear for including Japan. However, as is widely known, thalidomide a long time, cereblon, a substrate receptor of the CRL4 E3 was found to have serious teratogenic effects. Use during ubiquitin ligase was identified as a primary direct target by pregnancy is associated with developmental defects of the a new affinity technique. A growing body of evidence sug- limbs and ears.
    [Show full text]
  • Inozyme Pharma Expands Medical Leadership Team
    Inozyme Pharma Expands Medical Leadership Team Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials Boston, Mass., Nov. 14, 2019 – Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three industry veterans to its leadership team: • Pedro Huertas M.D., Ph.D., as Chief Medical Officer, • Gus Khursigara Ph.D., as Vice President of Medical Affairs and Clinical Operations, and • Catherine Nester, as Vice President of Physician and Patient Strategies. The executives will be instrumental in advancing Inozyme’s lead drug candidate, INZ-701, into clinical trials in 2020 for the treatment of patients with ENPP1 deficiency. INZ-701 is the first therapy that addresses the pathology of ENPP1 deficiency, including diseases such as generalized arterial calcification of infancy (GACI) type 1 and autosomal recessive hypophosphatemic rickets type 2 (ARHR2), both of which are rare and life-threatening manifestations of this enzyme deficiency. Inozyme Pharma received orphan drug designation for INZ-701 in the US and EU in 2018. “We are pleased and excited to welcome Pedro, Gus and Catherine to the Inozyme team,” said Axel Bolte, co-founder and chief executive officer of Inozyme. “Their expertise in orphan drug development – spanning medical affairs, regulatory affairs and clinical development – will strengthen and accelerate our ability to bring potentially life-saving medicines to people who urgently need effective treatments.” Dr. Huertas, a veteran of the pharmaceutical industry, has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies.
    [Show full text]
  • Faculty Disclosure
    Faculty Disclosure In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity. Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role AbbVie, Allergan/ Tobira Therapeutics Inc, Gilead Research Grant Research Balart Sciences Inc, Pfizer, Salix Pharmaceuticals AbbVie, Merck Honorarium Advisory Board Bau None N/A N/A Benz None N/A N/A AbbVie, Arbutus Biopharma, Dieterich Gilead Sciences, Inc., Bristol- Research Grant Consultant Myers Squibb, Merck Bayer HealthCare Pharmaceuticals, Gilead Sciences Honorarium Speaking, Consultant Inc. Bristol-Myers Squibb, Gilead Speaking, Advisory Sciences, Inc, Salix Honorarium Frenette Board Pharmaceuticals, Inc, Merck Intercept Pharmaceuticals Honorarium Advisor Conatus Pharmaceuticals Inc Honorarium Consulting Principle Investigator, Research Grant, Han Gilead Sciences,
    [Show full text]
  • AMGEN INC. V. SANOFI
    Case: 20-1074 Document: 159 Page: 1 Filed: 06/21/2021 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ AMGEN INC., AMGEN MANUFACTURING, LIMITED, AMGEN USA, INC., Plaintiffs-Appellants v. SANOFI, AVENTISUB LLC, FKA AVENTIS PHARMACEUTICALS INC., REGENERON PHARMACEUTICALS INC., SANOFI-AVENTIS U.S. LLC, Defendants-Appellees ______________________ 2020-1074 ______________________ Appeal from the United States District Court for the District of Delaware in Nos. 1:14-cv-01317-RGA, 1:14-cv- 01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA, Judge Richard G. Andrews. ______________________ JEFFREY A. LAMKEN, MoloLamken LLP, Washington, DC, filed a petition for rehearing en banc for plaintiffs-ap- pellants. Also represented by SARAH JUSTINE NEWMAN, MICHAEL GREGORY PATTILLO, JR.; SARA MARGOLIS, New York, NY; EMILY JOHNSON, ERICA S. OLSON, STEVEN TANG, STUART WATT, WENDY A. WHITEFORD, Amgen Inc., Thou- sand Oaks, CA; KEITH HUMMEL, Cravath Swaine & Moore LLP, New York, NY; WILLIAM G. GAEDE, III, McDermott Case: 20-1074 Document: 159 Page: 2 Filed: 06/21/2021 2 AMGEN INC. v. SANOFI Will & Emery LLP, Menlo Park, CA; CHRISTOPHER B. MEAD, Schertler Onorato Mead & Sears LLP, Washington, DC; JAMES L. HIGGINS, MELANIE K. SHARP, Young, Cona- way, Stargatt & Taylor, LLP, Wilmington, DE. Plaintiff- appellant Amgen Inc. also represented by SARAH CHAPIN COLUMBIA, McDermott, Will & Emery LLP, Boston, MA; LAUREN MARTIN, Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA. MATTHEW WOLF, Arnold & Porter Kaye Scholer LLP, Washington, DC, filed a response for defendants-appellees. Also represented by VICTORIA REINES; DAVID K. BARR, DANIEL REISNER, New York, NY; DEBORAH E.
    [Show full text]
  • FTSE Japan ESG Low Carbon Select
    2 FTSE Russell Publications 19 August 2021 FTSE Japan ESG Low Carbon Select Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country ABC-Mart 0.01 JAPAN Ebara 0.17 JAPAN JFE Holdings 0.04 JAPAN Acom 0.02 JAPAN Eisai 1.03 JAPAN JGC Corp 0.02 JAPAN Activia Properties 0.01 JAPAN Eneos Holdings 0.05 JAPAN JSR Corp 0.11 JAPAN Advance Residence Investment 0.01 JAPAN Ezaki Glico 0.01 JAPAN JTEKT 0.07 JAPAN Advantest Corp 0.53 JAPAN Fancl Corp 0.03 JAPAN Justsystems 0.01 JAPAN Aeon 0.61 JAPAN Fanuc 0.87 JAPAN Kagome 0.02 JAPAN AEON Financial Service 0.01 JAPAN Fast Retailing 3.13 JAPAN Kajima Corp 0.1 JAPAN Aeon Mall 0.01 JAPAN FP Corporation 0.04 JAPAN Kakaku.com Inc. 0.05 JAPAN AGC 0.06 JAPAN Fuji Electric 0.18 JAPAN Kaken Pharmaceutical 0.01 JAPAN Aica Kogyo 0.07 JAPAN Fuji Oil Holdings 0.01 JAPAN Kamigumi 0.01 JAPAN Ain Pharmaciez <0.005 JAPAN FUJIFILM Holdings 1.05 JAPAN Kaneka Corp 0.01 JAPAN Air Water 0.01 JAPAN Fujitsu 2.04 JAPAN Kansai Paint 0.05 JAPAN Aisin Seiki Co 0.31 JAPAN Fujitsu General 0.01 JAPAN Kao 1.38 JAPAN Ajinomoto Co 0.27 JAPAN Fukuoka Financial Group 0.01 JAPAN KDDI Corp 2.22 JAPAN Alfresa Holdings 0.01 JAPAN Fukuyama Transporting 0.01 JAPAN Keihan Holdings 0.02 JAPAN Alps Alpine 0.04 JAPAN Furukawa Electric 0.03 JAPAN Keikyu Corporation 0.02 JAPAN Amada 0.01 JAPAN Fuyo General Lease 0.08 JAPAN Keio Corp 0.04 JAPAN Amano Corp 0.01 JAPAN GLP J-REIT 0.02 JAPAN Keisei Electric Railway 0.03 JAPAN ANA Holdings 0.02 JAPAN GMO Internet 0.01 JAPAN Kenedix Office Investment Corporation 0.01 JAPAN Anritsu 0.15 JAPAN GMO Payment Gateway 0.01 JAPAN KEWPIE Corporation 0.03 JAPAN Aozora Bank 0.02 JAPAN Goldwin 0.01 JAPAN Keyence Corp 0.42 JAPAN As One 0.01 JAPAN GS Yuasa Corp 0.03 JAPAN Kikkoman 0.25 JAPAN Asahi Group Holdings 0.5 JAPAN GungHo Online Entertainment 0.01 JAPAN Kinden <0.005 JAPAN Asahi Intecc 0.01 JAPAN Gunma Bank 0.01 JAPAN Kintetsu 0.03 JAPAN Asahi Kasei Corporation 0.26 JAPAN H.U.
    [Show full text]
  • Critical Analysis of Valuation and Strategical Orientation of Merger
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018 https://doi.org/10.1080/14737167.2018.1417040 REVIEW Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry Raphaela Marie Louisa Dierks, Olivier Bruyère and Jean-Yves Reginster Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics, CHU Sart-Tilman, Liège, Belgium ABSTRACT ARTICLE HISTORY Introduction: The pharmaceutical industry is undergoing major shifts due to changing macro and Received 21 October 2017 micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on Accepted 11 December 2017 generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses KEYWORDS two completed deals in 2016 above 1bn USD. Thereafter one outlines the main motives behind M&A Pharmaceutical industry; deals and concluded by discussing whether M&A harms medical innovations. merger and acquisitions Areas covered: The paper is based on empirical study questioning existing literature in order to (M&A); valuation; inorganic critically analyse valuation and the strategical orientation of pharmaceutical companies growth; medical innovation; Expert commentary: Pharmaceutical companies understand the changing market conditions and non-core assets; drug favour their expertise. The restructuring of the industry moves to small niche companies (I.e. pipeline; tax inversion Biopharma or biotech companies) researching key innovations and big companies purchasing them to develop them, create clinical trials and distribute them as this is a costly manner Conclusion: One can expect more M&A deals during the next years focusing on value rather than volume. Pharmaceutical players resilient to the market changes may survive if they change their business model from a traditional vertical one to outsourcing and diversification including external players.
    [Show full text]
  • PULSE: Speaker Biographies March 2019
    PULSE: Speaker Biographies March 2019 Supported by @BIA_UK www.bioindustry.org In order of appearance: Dr Barbara Domayne-Hayman Entrepreneur-in-residence, Francis Crick Institute, CBO, Autifony Therapeutics Ltd and formerly Chairman, Puridify Barbara has worked on the commercial side of life sciences for thirty years, first in a large organisation (ICI/Zeneca/AstraZeneca), before transitioning to the entrepreneurial world of biotech. Barbara joined the Francis Crick Institute in January 2018 as Entrepreneur-in- residence. She is also Chief Business officer of Autifony, where she is responsible for strategic partnering, fundraising and commercial aspects of drug development for CNS disorders. In December 2017 Autifony signed a major collaboration with Boehringer Ingelheim. Barbara was also Chair of Puridify, a UCL spin-out with a breakthrough biotherapeutics purification technology, which was acquired by GE in November 2017. She chairs the LifeArc Seed Fund investment committee, and is on the Cambridge Enterprise Seed Fund Investment Committee. Previously, Barbara was CEO of Stabilitech, and she was Commercial Director at Arrow Therapeutics until the company was acquired by AstraZeneca. Barbara was also Senior Business Development Manager at Celltech. Barbara has a BA and D Phil in Chemistry from the University of Oxford, and is a Sloan Fellow from London Business School. Steve Bates, OBE CEO, BioIndustry Association Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
    [Show full text]